CHEMBIO DIAGNOSTIC SYSTEMS INC.

• TRUSTEES OF BOSTON UNIVERSITY

  UEI THL6A6JLE1S7

  $1M

  Subcontractor to this prime · 1 sub-award · latest Feb 3, 2026

  • Office of Assistant Secretary for Preparedness and Response
  • “THE OBJECTIVE OF THE PROPOSED PROGRAM IS TO DEVELOP AN ACCURATE RAPID POINT-OF-CARE (POC) TEST FOR IGA ANTIBODY DETECTION IN TYPHOID FEVER USING CHEMBIO PATENTED DUAL PATH PLATFORM (DPP) TECHNOLOGY. IN THE PRESENT STAGE, WE WILL REFINE AND VERIFY THE ALPHA-PROTOTYPE DESIGN BASED ON DETECTION OF IGA ANTIBODIES TO LPS AND HLYE ANTIGENS OF SALMONELLA ENTERICA SEROVAR TYPHI. THE DPP TYPHOID IGA ASSAY WILL BE VALIDATED BY MANUFACTURING THREE DEVICE LOTS AND CONDUCTING PRE-CLINICAL EVALUATIONS AND REQUIRED ANALYTICAL STUDIES. DPP TYPHOID IGA ASSAY OFFERS SIGNIFICANT ADVANTAGES OVER THE OTHER RAPID DIAGNOSTICS AVAILABLE ON THE MARKET. IN CONTRAST TO ITS COMPETITORS TARGETING IGM AND/OR IGG ANTIBODIES, IT DETECTS IGA ANTIBODIES TO HLYE PROTEIN AND LPS, A MORE ACCURATE ANALYTE FOR RELIABLE SERODIAGNOSIS OF ACUTE INFECTION, AS DEMONSTRATED IN THREE INDEPENDENT TEST EVALUATION STUDIES PUBLISHED IN PEER-REVIEWED JOURNALS. THE DPP TYPHOID IGA ASSAY REQUIRES ONLY 10 ΜL WHOLE BLOOD, SERUM, OR PLASMA TO PRODUCE RESULTS WITHIN 15-20 MINUTES EITHER BY VISUAL READING OR BY USING AN AFFORDABLE PORTABLE ANALYZER FOR MORE OBJECTIVE TEST INTERPRETATION, HENCE FURTHER IMPROVING DIAGNOSTIC ACCURACY. THE DPP TYPHOID IGA ASSAY IS EXPECTED TO BE RELATIVELY INEXPENSIVE TO MANUFACTURE, IS SUITABLE FOR USE AT THE POINT OF CARE SETTINGS, AND REQUIRES ONLY MINIMAL TRAINING, MAKING IT AN IDEAL DIAGNOSTIC SOLUTION FOR LOW- TO MIDDLE-INCOME COUNTRIES.”

No reported sub-awards as a prime contractor.

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.